[Cost-effective analysis of rotation from sustained-release morphine tablet to transdermal fentanyl of matrix type or sustained-release oxycodone tablet].
The present study was undertaken to determine the pharmacoeconomics of switching from sustained-release morphine tablet to matrix type (MT) of transdermal fontanel or sustained-release Oxycodone tablet. Cost-effective analysis was performed using a simulation model along with decision analysis. The analysis was done from the payer's perspective. The cost-effective ratio/patient of transdermal MT fontanel (22, 539 yen)was lower than that of sustained -release Oxycodone tablet (23, 630 yen), although a sensitivity analysis could not indicate that this result was reliable. These results suggest the possibility that transdermal MT fontanel was much less expensive than a sustained-release Oxycodone tablet.
Ise
Yuya
Y
Dept. of Pharmaceutical Service, Nippon Medical School Hospital.
Wako
Tetsuya
T
Miura
Yoshihiko
Y
Katayama
Shirou
S
Shimizu
Hisanori
H
D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000191:economics*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D003663:Decision Trees; D003692:Delayed-Action Preparations; D005283:Fentanyl / Q000008:administration & dosage* / Q000191:economics*; D006801:Humans; D007564:Japan; D009020:Morphine / Q000008:administration & dosage* / Q000191:economics*; D010098:Oxycodone / Q000008:administration & dosage* / Q000191:economics*; D013607:Tablets
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D013607:Tablets; D009020:Morphine; D010098:Oxycodone; D005283:Fentanyl